For the quarter ending 2026-03-31.
| Income Statement | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Revenue | 0 | 5,485 | 0 | 1,986 |
| Research and development | 33,809 | 24,952 | 25,745 | 20,141 |
| General and administrative | 9,677 | 8,833 | 8,279 | 8,598 |
| Impairment of long-lived assets | - | 0 | 0 | - |
| Total operating expenses | 43,486 | 33,785 | 34,024 | 28,739 |
| Loss from operations | -43,486 | -28,300 | -34,024 | -26,753 |
| Change in fair value of warrant liability | 0 | 736 | 292 | 273 |
| Change in fair value of term loan | 1,470 | 1,643 | 1,534 | 1,461 |
| Interest income | 2,586 | 2,870 | 3,169 | 1,859 |
| Interest expense | 9 | 12 | 15 | 17 |
| Other income (expense) | -31 | -30 | -37 | -237 |
| Total other income (expense), net | 1,076 | 449 | 1,291 | -129 |
| Net loss | -42,410 | -27,851 | -32,733 | -26,882 |
| Basic EPS | -0.12 | -0.078 | -0.09 | -0.09 |
| Diluted EPS | -0.12 | -0.078 | -0.09 | -0.09 |
| Basic Average Shares | 366,632,827 | 358,243,055 | 353,309,524 | 297,988,978 |
| Diluted Average Shares | 366,632,827 | 358,243,055 | 353,309,524 | 297,988,978 |
Taysha Gene Therapies, Inc. (TSHA)
Taysha Gene Therapies, Inc. (TSHA)